Advances in Microfluidics for the Implementation of Liquid Biopsy in Clinical Routine

Teixeira, Alexandra; Carneiro, Adriana; Piairo, Paulina; Xavier, Miguel; Ainla, Alar; Lopes, Cláudia Lorena Ribeiro; Sousa-Silva, Maria; Dias, Armando; Martins, Ana Sofia; Rodrigues, Carolina; Pereira, Ricardo; Pires, Liliana R.; Abalde‐Cela, Sara; Diéguez, Lorena

doi:10.1007/978-3-031-04039-9_22

Cited by 3 publications

(3 citation statements)

References 220 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[55] Microfluidics technology has become a highly effective tool for precisely identifying, capturing, and analyzing cancer-derived material, such as CTCs and clusters in peripheral blood. [9,56] Increased CTCs levels on peripheral blood are directly correlated with a low patient prognosis; therefore, their capture and analysis are of utmost clinical importance. Similarly, other biomarkers present in blood plasma (or other bodily fluids like urine or saliva), [57] such as circulating tumor DNA (ctDNA), tumor-derived extracellular vesicles (EVs), or other proteins (e.g., antibodies), can be employed for liquid biopsy applications.…”

Section: Microfluidic Systems For Trapping Cancer-derived Material: C...mentioning

confidence: 99%

Cancer Traps: Implantable and On‐Chip Solutions for Early Cancer Detection and Treatment

Caballero

Reis

Kundu

2023

Adv Materials Technologies

View full text Add to dashboard Cite

Cancer continues to be a major global health issue causing millions of deaths annually. While traditional therapeutic methods may be effective in many cases, they may not be suitable for highly metastatic cancers. Moreover, the late detection of tumors, when they have already spread and are harder to treat, further exacerbates the challenge in managing this disease. As a result, there is a growing interest in developing complementary tissue‐engineered approaches for early cancer diagnosis and treatment to enhance patient recovery. Bioengineered cancer traps have gained significant attention due to their efficacy and ease of use. These trapping systems employ (bio)chemical and mechanical strategies to selectively capture and limit the spread of cancer cells, leading to their eradication from the body. Furthermore, when integrated into microfluidic devices, these cancer traps‐on‐a‐chip can be used for liquid biopsy and the early detection of circulating tumor cells and other tumor‐derived material, allowing for precision medicine treatments. Herein, this innovative approach to cancer theranostics, including its mechanism of action, current stage of development, and potential advantages and limitations is discussed.

show abstract

Section: Microfluidic Systems For Trapping Cancer-derived Material: C...mentioning

confidence: 99%

Cancer Traps: Implantable and On‐Chip Solutions for Early Cancer Detection and Treatment

Caballero

Reis

Kundu

2023

Adv Materials Technologies

View full text Add to dashboard Cite

show abstract

“…in the cellular compartment or bodily fluids. However, it is worth emphasizing that the measurement of physiological parameters on-chip must be trustful and already clinically validated [ 55 , 56 ].…”

Section: Organs-on-a-chip: Rethinking the Canonical Vision Of Tissue/...mentioning

confidence: 99%

Boosting the Clinical Translation of Organ-on-a-Chip Technology

2022

View full text Add to dashboard Cite

Organ-on-a-chip devices have become a viable option for investigating critical physiological events and responses; this technology has matured substantially, and many systems have been reported for disease modeling or drug screening over the last decade. Despite the wide acceptance in the academic community, their adoption by clinical end-users is still a non-accomplished promise. The reasons behind this difficulty can be very diverse but most likely are related to the lack of predictive power, physiological relevance, and reliability necessary for being utilized in the clinical area. In this Perspective, we briefly discuss the main attributes of organ-on-a-chip platforms in academia and how these characteristics impede their easy translation to the clinic. We also discuss how academia, in conjunction with the industry, can contribute to boosting their adoption by proposing novel design concepts, fabrication methods, processes, and manufacturing materials, improving their standardization and versatility, and simplifying their manipulation and reusability.

show abstract

“…Microfluidic devices have been successfully used for sizebased, [14][15][16][17] immune-based, 18,19 or chromatographic-based separation, 20 for cell encapsulation, [21][22][23] and also microfluidic flow cytometry. [24][25][26][27][28] Furthermore, microfluidic devices also offer high efficiency for processing complex fluids with minimal damage to the cells contained in these fluids, even the most sensitive. [29][30][31][32] For example, Ribeiro-Samy et al demonstrated the isolation of circulating tumor cells (CTCs) from whole blood using pillar structures to separate the cells of interest from the other blood cells, based on size and deformability.…”

Section: Introductionmentioning

confidence: 99%

Isolation of acute myeloid leukemia blasts from blood using a microfluidic device

Teixeira,

Sousa-Silva,

Chícharo

et al. 2024

Analyst

Self Cite

View full text Add to dashboard Cite

show abstract

Advances in Microfluidics for the Implementation of Liquid Biopsy in Clinical Routine

Cited by 3 publications

References 220 publications

Cancer Traps: Implantable and On‐Chip Solutions for Early Cancer Detection and Treatment

Cancer Traps: Implantable and On‐Chip Solutions for Early Cancer Detection and Treatment

Boosting the Clinical Translation of Organ-on-a-Chip Technology

Isolation of acute myeloid leukemia blasts from blood using a microfluidic device

Contact Info

Product

Resources

About